FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:1863-1865 November 1, 2007 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Sakuramoto, S. PubMed Citation

Gastric cancer is a leading cause of illness and death from cancer worldwide, with nearly a million new cases diagnosed each year and a 5-year survival rate of less than 20% among patients in most parts of the world other than Japan, where the rate is closer to 60%.¹ Early dissemination of the disease through the lymphatic system, blood, and peritoneum has limited the ability of optimal surgery to cure, except in patients with relatively early tumors. The detection of early disease has remained elusive in Europe and North America, but there has been some success in the East, particularly . . . [Full Text of this Article]

Source Information

From the Department of Medicine, Royal Marsden Hospital, London and Surrey, United Kingdom.

This article has been cited by other articles:

• Liakakos, T., Fatourou, E., Ziogas, D., Lykoudis, E., Roukos, D. H. (2008). Targeting VEGF, EGFR, and Other Interacting Pathways for Gastric Cancer--Promises and Reality. Ann. Surg. Oncol. 15: 2981-2982 [Full Text]  
• Lieto, E., Ferraraccio, F., Orditura, M., Castellano, P., LaMura, A., Pinto, M., Zamboli, A., DeVita, F., Galizia, G. (2008). Integrated Therapy in Localized Gastric Cancer: Targeted and Tailored Approach. Ann. Surg. Oncol. 15: 2983-2985 [Full Text]